ArticleResearch square2026
MRI-derived periventricular diffusivity contextualizes plasma pTau217 associations with Alzheimer pathology: a discovery-validation study.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Background: Plasma phosphorylated tau 217 (pTau217) is a promising scalable marker of Alzheimer pathology, but discordance with positron emission tomography (PET) limits context-free interpretation. We tested whether magnetic resonance imaging (MRI)-derived periventricular diffusivity (PVeD) modifies associations between pTau217 and Alzheimer pathology. Methods: In this observational discovery-validation study, standardized pTau217 × PVeD interactions were tested for amyloid PET, tau PET, structural and vascular MRI, and cognitive outcomes in 602 participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) and 2,313 participants from the Health and Aging Brain Study-Health Disparities (HABS-HD). Analyses were adjusted for prespecified covariates and false discovery rate correction. Results: In ADNI, pTau217 associations with amyloid Centiloid (interaction β = -0.096, 95% confidence interval [CI] - 0.154 to - 0.037; adjusted P = .018) and meta-temporal tau PET (β = -0.092, 95% CI - 0.158 to - 0.027; adjusted P = .018) were stronger at lower PVeD. Among participants with high pTau217, low PVeD was associated with faster cognitive decline than high PVeD (difference = - 0.100 Preclinical Alzheimer Cognitive Composite [PACC] units/year, 95% CI - 0.161 to - 0.038; adjusted P = .002). HABS-HD replicated the amyloid interaction (β = -0.109, 95% CI - 0.147 to - 0.070; adjusted P < .001) and multiple tau PET interactions; the high-pTau217/low-PVeD profile also declined faster (difference = - 0.037 PACC units/year; adjusted P = .002). Conclusions: PVeD reproducibly contextualized associations between plasma pTau217 and PET-defined Alzheimer pathology across cohorts with different participant composition, pTau217 assays, PET tracers, and cognitive measures. The findings motivate prospective evaluation of MRI-informed interpretation of blood biomarkers, but PVeD is an indirect diffusion marker and the observational design does not establish mechanism, clinical utility, or decision thresholds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.